Pfizer restarts production at tornado-hit plant, expects supply issues to persist into 2024
Pfizer has restarted most of its manufacturing lines that were impacted by tornado damage earlier this summer at its facility in Rocky Mount, North Carolina, but supply interruptions for some medicines may persist until mid-2024, the company said Monday.
Pfizer restarted production of 13 medicines made on lines impacted by the damage based on patient need and inventory levels, the company said. As part of these efforts, Pfizer said it launched one line in the site’s new sterile injectable manufacturing area, which the FDA approved earlier this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.